文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

静脉-静脉体外膜氧合治疗首7天内触珠蛋白耗竭与急性呼吸窘迫综合征患者死亡率增加及不良结局相关

HAPTOGLOBIN DEPLETION DURING THE FIRST 7 DAYS OF VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION THERAPY IS ASSOCIATED WITH INCREASED MORTALITY AND ADVERSE OUTCOMES IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME.
PubMed 文献 · Shock · 2024-03-24
一句话结论ARDS接受静脉-静脉ECMO治疗者,首7天内血浆触珠蛋白降至<0.39 g/L与28天死亡率43.5% vs 25.3%相关,作者认为可能受益于密切监测溶血。

本研究为单中心回顾性分析,纳入2007年1月至2018年12月一家三级ARDS转诊中心435例接受静脉-静脉ECMO治疗的ARDS患者。触珠蛋白耗竭定义为ECMO启动后首周内血浆触珠蛋白浓度降至<0.39 g/L,耗竭组269例与非耗竭组比较,主要终点28天死亡率43.5%(95%CI 37.52-49.66)vs 25.3%(19.03-32.74),P<0.001。次要终点中耗竭组无器官功能障碍天数更少(SHR 0.35,95%CI 0.25-0.50,P<0.001),28天内成功脱离肾脏替代治疗、血管升压药和ECMO的机会均更低。作者认为首周触珠蛋白耗竭的患者可能受益于密切监测溶血、早期发现并消除病因,并可能是未来触珠蛋白补充治疗的潜在候选者。

要点

  • ARDS静脉-静脉ECMO患者首7天内血浆触珠蛋白<0.39 g/L定义为耗竭,耗竭组269例28天死亡率43.5%(95%CI 37.52-49.66)vs 非耗竭组25.3%(19.03-32.74),P<0.001。
  • 触珠蛋白耗竭组无器官功能障碍天数更少:SHR 0.35(95%CI 0.25-0.50),P<0.001。
  • 触珠蛋白耗竭组28天内成功脱离肾脏替代治疗的机会更低:SHR 0.50(95%CI 0.32-0.79),P<0.001。
  • 触珠蛋白耗竭组28天内成功脱离血管升压药治疗的机会更低:SHR 0.39(95%CI 0.28-0.54),P<0.001;成功脱离ECMO的机会也更低:SHR 0.41(95%CI 0.30-0.57),P<0.001。
  • 初始触珠蛋白<0.66 g/L者发生触珠蛋白耗竭的风险高于初始触珠蛋白≥0.66 g/L者。

适用人群与场景

  • 2007年1月至2018年12月一家三级ARDS转诊中心收治的接受静脉-静脉ECMO治疗的ARDS患者435例。

诊断标准与关键阈值

  • 触珠蛋白耗竭:ECMO启动后首周内血浆触珠蛋白浓度降至<0.39 g/L。
  • 初始触珠蛋白<0.66 g/L者发生触珠蛋白耗竭的风险高于初始触珠蛋白≥0.66 g/L者。

研究设计与关键结果

  • 研究类型:单中心回顾性分析;样本量435例ARDS接受静脉-静脉ECMO治疗患者;中心数:一家三级ARDS转诊中心;时间范围2007年1月至2018年12月。
  • 分组:触珠蛋白耗竭组269例 vs 非耗竭组;主要终点28天死亡率43.5%(95%CI 37.52-49.66)vs 25.3%(19.03-32.74),P<0.001。
  • 次要终点:触珠蛋白耗竭组无器官功能障碍天数更少,SHR 0.35(95%CI 0.25-0.50),P<0.001。
  • 次要终点:触珠蛋白耗竭组28天内成功脱离肾脏替代治疗的机会更低,SHR 0.50(95%CI 0.32-0.79),P<0.001。
  • 次要终点:触珠蛋白耗竭组28天内成功脱离血管升压药治疗的机会更低,SHR 0.39(95%CI 0.28-0.54),P<0.001。
  • 次要终点:触珠蛋白耗竭组28天内成功脱离ECMO治疗的机会更低,SHR 0.41(95%CI 0.30-0.57),P<0.001。
  • 初始触珠蛋白<0.66 g/L者发生触珠蛋白耗竭的风险高于初始触珠蛋白≥0.66 g/L者。

证据类型、等级与局限

  • 证据类型:回顾性分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ECMO治疗首周内出现触珠蛋白耗竭的患者可能受益于密切监测溶血,并早期发现和消除潜在病因。
  • 作者认为,触珠蛋白耗竭患者可能是未来触珠蛋白补充治疗的潜在候选者,以预防细胞游离血红蛋白清除系统过载。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Hemolysis is a frequent complication in patients with sepsis, ARDS, or extracorporeal membrane oxygenation (ECMO). Haptoglobin (Hp) can scavenge released cell-free hemoglobin (CFH). Hemolysis and low plasma concentrations of Hp may be independently associated with mortality in critically ill patients. Methods: This study used a retrospective analysis of 435 patients with ARDS and veno-venous ECMO therapy, admitted to a tertiary ARDS referral center (01/2007-12/2018). Hp depletion was defined as decrease in plasma Hp concentration <0.39 g/L within the first week after ECMO initiation. Patients with Hp depletion were compared to patients without Hp depletion. The primary endpoint was 28-day mortality. Secondary endpoints included organ dysfunction-free, renal replacement therapy-free, vasopressor-free, and ECMO-free composites. Results: Patients with Hp depletion (n = 269) had a significantly higher mortality 28 days after ECMO initiation compared to patients without Hp depletion (43.5% [95% CI 37.52-49.66] vs. 25.3% [19.03-32.74], P < 0.001). Furthermore, patients with Hp depletion had fewer organ dysfunction-free days (subdistribution hazard ratio [SHR] 0.35 [95% CI 0.25-0.50], P < 0.001), lower chances for successful weaning from renal replacement therapy (SHR 0.50 [0.32-0.79], P < 0.001), vasopressor therapy (SHR 0.39 [0.28-0.54], P < 0.001), and ECMO therapy (SHR 0.41 [0.30-0.57], P < 0.001) within 28 days after ECMO initiation. Patients with initial Hp <0.66 g/L had higher risks for Hp depletion than patients with initial Hp ≥0.66 g/L. Conclusion: Patients with Hp depletion within the first week of ECMO therapy might benefit from close monitoring of hemolysis with early detection and elimination of the underlying cause. They might be potential candidates for future Hp supplementation therapy to prevent overload of the CFH-scavenger system.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Bünger V, Hunsicker O, Krannich A, et al. HAPTOGLOBIN DEPLETION DURING THE FIRST 7 DAYS OF VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION THERAPY IS ASSOCIATED WITH INCREASED MORTALITY AND ADVERSE OUTCOMES IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME. Shock. 2024. PMID: 38661177. doi:10.1097/SHK.0000000000002352

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。